Introduction Stroke is one of the leading causes of mortality and morbidity globally. Atrial
fibrillation (AF) is the most common sustained cardiac arrhythmia. It is set to reach epidemic …

After decades of warfarin being the only oral anticoagulant (OAC) widely available for stroke
prevention in atrial fibrillation, four direct OACs (apixaban, dabigatran, edoxaban and …

Abstract The Rotterdam Study is an ongoing prospective cohort study that started in 1990 in
the city of Rotterdam, The Netherlands. The study aims to unravel etiology, preclinical …

Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation …

Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …

Aims Non-vitamin K oral anticoagulants are safe and effective for stroke prevention in
patients with atrial fibrillation (AF). Data on the safety and efficacy of edoxaban in routine …

Importance Many patients with nonvalvular atrial fibrillation (NVAF) are at a high risk of
gastrointestinal (GI) bleeding due to conditions including older age; stage III to V chronic …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

Background and purpose Prospectively collected data comparing the safety and
effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective …

Atrial fibrillation (AF) is associated with an increased risk of stroke, which can be prevented
by the use of oral anticoagulation. Although non-vitamin K antagonist oral anticoagulants …